2022
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.
Moutafi M, Robbins C, Yaghoobi V, Fernandez A, Martinez-Morilla S, Xirou V, Bai Y, Song Y, Gaule P, Krueger J, Bloom K, Hill S, Liebler D, Fulton R, Rimm D. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Laboratory Investigation 2022, 102: 1101-1108. PMID: 36775350, DOI: 10.1038/s41374-022-00804-9.Peer-Reviewed Original ResearchConceptsHER2 expressionBreast cancerAttomol/HER2 proteinBreast cancer patientsBreast cancer casesOptimal patient careLevels of HER2Trastuzumab deruxtecanT-DXdCancer patientsLow HER2Cancer casesConventional assaysHER2Patient careAntibody concentrationsQuantitative immunofluorescenceAntibody drugsCancerCell linesAssaysExpressionHER2 detectionLower range
2016
The IN/OUT assay: a new tool to study ciliogenesis
Kukic I, Rivera-Molina F, Toomre D. The IN/OUT assay: a new tool to study ciliogenesis. Cilia 2016, 5: 23. PMID: 27493724, PMCID: PMC4972980, DOI: 10.1186/s13630-016-0044-2.Peer-Reviewed Original ResearchCiliary pocketCiliary transmembrane proteinsPlasma membrane invaginationsDeep plasma membrane invaginationsPrimary cilia assemblyCilia assemblyMembrane invaginationsTransmembrane proteinPrimary ciliaCellular antennaCilia lengthMolecular characterizationMost ciliaFunctional studiesCiliogenesisCiliaNew toolRPE cellsCellsAssaysAntibody accessEHD1New assayPocketConventional assays
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply